Back to Search Start Over

Review of methods for detecting glycemic disorders

Authors :
Mary K. Rhee
Ralph A. DeFronzo
Cristina Bianchi
Nouran Ibrahim
Antonio Ceriello
David R. Owens
Mariana P. Monteiro
Michael Bergman
Maria Paula Macedo
Louis Monnier
Brenda Dorcely
João Sérgio Neves
Giorgio Sesti
Jose Luiz Medina
Melania Manco
Rogério T. Ribeiro
Stefano Del Prato
Claude Colette
Teresa Vanessa Fiorentino
Martin Buysschaert
Lawrence S. Phillips
Ram Jagannathan
Celeste K. Cravalho
Stephanie T. Chung
João Filipe Raposo
Muhammad A. Abdul-Ghani
Source :
Diabetes Res Clin Pract
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.

Details

ISSN :
01688227
Volume :
165
Database :
OpenAIRE
Journal :
Diabetes Research and Clinical Practice
Accession number :
edsair.doi.dedup.....60ed4bb945773f29cf23823f3c73e6c6
Full Text :
https://doi.org/10.1016/j.diabres.2020.108233